Twice-yearly lenacapavir pre-exposure prophylaxis (PrEP) can be a good option for teens and young adults, a group that often struggles with consistent adherence to daily prevention pills. Worldwide, adolescents and young adults have a higher likelihood of HIV acquisition compared with older people. In June, the Food and Drug Administration approved lenacapavir PrEP (Yeztugo) based on impressive data from the Phase III PURPOSE 1 and PURPOSE 2 studies. All participants in PURPOSE 1 were young women ages 16 to 25, a group that bears the brunt of the HIV epidemic in sub-Saharan Africa. In PURPOSE 2, about a third of the gay men and gender-diverse people in the study were 16 to 25. Lenacapavir PrEP demonstrated high effectiveness for young peo--ple. There were zero new HIV acquisitions in PURPOSE 1. In PURPOSE 2, the two people who seroconverted in the lenacapavir group were in the 16-to-25 age group, but the vast majority of young participants remained free of HIV. There were no clinically relevant differences by age in the drug’s pharmacokinetics or safety.